On June 11, Peking University Shougang Hospital completed its first radical cystectomy using the SHURUI® single-port robotic system—a major leap in minimally invasive urologic oncology. Led by Dr. Gang Wang, the surgical team successfully performed a total bladder removal and intracorporeal ileal conduit reconstruction in a 62-year-old bladder cancer patient with challenging pelvic anatomy.
The SHURUI® surgical system’s flexible snake-like instruments enabled high-precision dissection and suturing in a confined space, through a single small incision. The procedure minimized trauma and blood loss, allowing the patient to ambulate the next day.
This landmark case demonstrates the transformative potential of domestic single-port robotic technology in complex pelvic surgeries. It also reflects the alignment of top-tier clinical expertise with China’s innovation-driven healthcare strategy—bridging AI-powered surgical tools with real-world outcomes, and propelling the future of ultra-minimally invasive surgery.
Important Notes
The Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has been approved by the National Medical Products Administration (NMPA) in China for urology and gynecology laparoscopic surgeries. Surgeons who wish to learn the surgical operations of the SHURUI robot should contact Beijing Surgerii Robotics Co., Ltd. to participate in the official training program. Patients who want to participate in the registered clinical trials of the SHURUI robot should contact the official cooperative hospitals of Surgerii and consult with surgeons to determine their suitability for surgery with the SHURUI robot. Both surgeons and patients should carefully understand all information regarding the performance of surgeries by the SHURUI robot and its potential risks.
Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other
trademarks and may not be used without permission.
